Patients with neuregulin 1 (NRG1) rearranged cancer are suitable for the theranostic approach and targeted therapy
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
35989083
DOI
10.48095/ccko2022271
PII: 131525
Knihovny.cz E-resources
- Keywords
- ERBB 2 protein, ERBB 3 protein, NRG 1 protein, molecular targeted therapies, molecular targeted therapy, neuregulin 1, solid tumors,
- MeSH
- Adenocarcinoma of Lung drug therapy genetics metabolism MeSH
- Precision Medicine MeSH
- Humans MeSH
- Lung Neoplasms drug therapy genetics metabolism MeSH
- Neoplasms * genetics metabolism MeSH
- Neuregulin-1 * genetics metabolism MeSH
- Antineoplastic Agents therapeutic use MeSH
- Receptor, ErbB-2 genetics metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Neuregulin-1 * MeSH
- NRG1 protein, human MeSH Browser
- Antineoplastic Agents MeSH
- Receptor, ErbB-2 MeSH
INTRODUCTION: Neuregulin 1 (NRG1) gene fusion was detected in a wide range of carcinomas. It is most frequently present in lung adenocarcinomas, especially in KRAS and BRAF wild-type cases. PURPOSE: We present a newly described diverse group of NRG1 rearranged carcinomas. The paper explains basic molecular principles associated with this oncogenic driver. It consists of ERBB3 (HER3) and ERBB2 (HER2) receptor activation with downstream activation of PIK and MAPK canonical pathways. The experience with new therapeutic modalities is summarized. CONCLUSIONS: So far, the global results of cytotoxic, immune and targeted therapies were dis-appointing. Further research (including two studies in Europe) is underway, developing new therapeutic strategies and examining this cancer bio-logy. In the meantime, it is possible to dia-gnose NRG1 rearranged carcinomas in the Czech Republic since mRNA next generation sequencing (NGS) analysis is readily available.
References provided by Crossref.org
